Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Show more

Location: 9237 East Via de Ventura Boulevard, Scottsdale, AZ, 85258, United States | Website: https://journeymedicalcorp.com | Industry: Drug Manufacturers - Specialty & Generic | Sector: Healthcare


Market Cap

166.6M

52 Wk Range

$3.54 - $8.25

Previous Close

$7.15

Open

$7.20

Volume

352,367

Day Range

$7.20 - $8.00

Enterprise Value

171.4M

Cash

21.07M

Avg Qtr Burn

-1.735M

Insider Ownership

30.68%

Institutional Own.

29.59%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.